Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Lippman

Showing results (221-230 of 340) with videos related to

Pageof 34
Sort By:
Journal of the National Cancer Institute|June 29, 2007
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention TrialCarol M Moinpour, Amy K Darke, Gary W Donaldson, et al.
The Prostate|June 8, 2020
The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention TrialSusan Chadid, John R Barber, William G Nelson, et al.
JCO Precision Oncology|May 7, 2019
Revisiting Epidermal Growth Factor Receptor (<i>EGFR</i>) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced MalignanciesShumei Kato, Ryosuke Okamura, Manvita Mareboina, et al.
Scientific Reports|April 7, 2020
Author Correction: Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in TaiwanXifeng Wu, Chi Pang Wen, Yuanqing Ye, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 18, 2010
Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodulesGiulia Veronesi, Eva Szabo, Andrea Decensi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2016
Leveraging premalignant biology for immune-based cancer preventionAvrum Spira, Mary L Disis, John T Schiller, et al.
Oncotarget|September 30, 2015
Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncologySandip P Patel, Maria Schwaederle, Gregory A Daniels, et al.
The New England Journal of Medicine|May 28, 2004
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliterIan M Thompson, Donna K Pauler, Phyllis J Goodman, et al.
Journal of the National Cancer Institute|February 25, 2014
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer riskAlan R Kristal, Amy K Darke, J Steven Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramificationsYoshitsugu Mitani, Pulivarthi H Rao, Sankar N Maity, et al.
Pageof 34

Showing results (221-230 of 340) with videos related to

Sort By:
Pageof 34
Journal of the National Cancer Institute|June 29, 2007
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention TrialCarol M Moinpour, Amy K Darke, Gary W Donaldson, et al.
The Prostate|June 8, 2020
The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention TrialSusan Chadid, John R Barber, William G Nelson, et al.
JCO Precision Oncology|May 7, 2019
Revisiting Epidermal Growth Factor Receptor (<i>EGFR</i>) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced MalignanciesShumei Kato, Ryosuke Okamura, Manvita Mareboina, et al.
Scientific Reports|April 7, 2020
Author Correction: Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in TaiwanXifeng Wu, Chi Pang Wen, Yuanqing Ye, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 18, 2010
Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodulesGiulia Veronesi, Eva Szabo, Andrea Decensi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 18, 2016
Leveraging premalignant biology for immune-based cancer preventionAvrum Spira, Mary L Disis, John T Schiller, et al.
Oncotarget|September 30, 2015
Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncologySandip P Patel, Maria Schwaederle, Gregory A Daniels, et al.
The New England Journal of Medicine|May 28, 2004
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliterIan M Thompson, Donna K Pauler, Phyllis J Goodman, et al.
Journal of the National Cancer Institute|February 25, 2014
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer riskAlan R Kristal, Amy K Darke, J Steven Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramificationsYoshitsugu Mitani, Pulivarthi H Rao, Sankar N Maity, et al.
Pageof 34